Key recommendations of the SRIA update are:
- Focus on unmet medical needs where only Nanomedicine can make the difference by providing currently lacking diagnostic and therapeutic options
- Facilitate the matching of nanotechnology features with other Key Enabling Technologies (KETs) for new smart and connected products and devices,
- Optimize the implementation of medical innovations into the healthcare systems by balancing benefits for patients with cost constrains and industrial return on investment
- Improve competitiveness of European healthcare economy at the global market
The SRIA contains detailed recommendations for R&D topics on selected diseases that affect a large number of patients (cardio-vascular diseases, cancer, diabetes, neurodegenerative diseases, infection diseases, osteoarticular pathologies and others). Moreover, the focus is set on translation of research results, i.e. the capacity to move their lab proof of concept towards an approved and certified product available for patients on the healthcare market.For the first time, the best Nanomedicine experts and scientists from the ETPN and EuroNanoMed II have joined forces to design the new SRIA for Nanomedicine, with the objective to reflect the future challenges that the European Community will have to address. ETPN has recently celebrated its 10th
anniversary and this update of the SRIA reflects the tremendous advancements and progress done since its inception for the global benefit of patients and EU citizens.